Concert Pharmaceuticals (NASDAQ:CNCE) announced its quarterly earnings data on Thursday. The biotechnology company reported ($0.93) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.62) by ($0.31), MarketWatch Earnings reports. Concert Pharmaceuticals had a negative net margin of 533.31% and a negative return on equity of 29.33%. The business had revenue of $1.01 million for the quarter, compared to analysts’ expectations of $16.08 million.
NASDAQ CNCE traded up $0.69 during trading hours on Friday, hitting $10.65. 229,600 shares of the company’s stock traded hands, compared to its average volume of 249,256. Concert Pharmaceuticals has a 52-week low of $9.21 and a 52-week high of $21.00. The stock has a market cap of $234.35 million, a PE ratio of -4.44 and a beta of 0.89.
Several analysts recently issued reports on the stock. Zacks Investment Research cut shares of Concert Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Tuesday, March 5th. BidaskClub raised shares of Concert Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, March 6th. TheStreet cut shares of Concert Pharmaceuticals from a “c-” rating to a “d” rating in a research note on Friday, March 1st. HC Wainwright reaffirmed a “buy” rating on shares of Concert Pharmaceuticals in a research note on Friday, March 1st. Finally, ValuEngine cut shares of Concert Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, January 4th. Four research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Concert Pharmaceuticals has a consensus rating of “Buy” and a consensus price target of $20.00.
TRADEMARK VIOLATION NOTICE: “Concert Pharmaceuticals (CNCE) Announces Quarterly Earnings Results, Misses Expectations By $0.31 EPS” was originally posted by Week Herald and is owned by of Week Herald. If you are viewing this article on another publication, it was illegally stolen and republished in violation of United States and international copyright and trademark legislation. The correct version of this article can be read at https://weekherald.com/2019/05/03/concert-pharmaceuticals-cnce-announces-quarterly-earnings-results-misses-expectations-by-0-31-eps.html.
Concert Pharmaceuticals Company Profile
Concert Pharmaceuticals, Inc operates as a clinical stage biopharmaceutical company. The company discovers and develops novel small molecule drugs for use in the treatment autoimmune and inflammatory diseases, and central nervous systems disorders. Its product candidates include AVP-786, a combination of deudextromethorphan and an ultra-low dose of quinidine, which is in Phase 3 clinical trials for the treatment of neurologic and psychiatric disorders, including agitation associated with Alzheimer's disease; CTP-730, a deuterated analog of apremilast that has completed the Phase 1 clinical trials for the treatment of inflammation or cancer; JZP-386, a once-nightly oxybate product; and CTP-543, which is in Phase 1 clinical trials for use in the treatment of alopecia areata.
Featured Story: What is the Quick Ratio?
Receive News & Ratings for Concert Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Concert Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.